Alembic Pharmaceuticals Analysis (April 2026) | Price Development & Price Target

Alembic Pharmaceutic...

NSEI:APLLTD

Rp 655,95

Rp-0,25 (-0,04%)

655,95 Rp

Rp-0,25 (-0,04%)

End-of-day quote: 04/07/2026

Alembic Pharmaceuticals Stock Value

The analyst rating for NSEI:APLLTD is currently Outperform.

Outperform

Alembic Pharmaceuticals Company Info

EPS Growth 5Y

-7,90%

Market Cap

Rp128,99 B

Long-Term Debt

Rp2,00 B

Quarterly earnings

N/A

Dividend

Rp11,02

Dividend Yield

1,68%

Founded

1907

Industry

Health Care

Country

India

Website

Alembic Pharmaceuticals

ISIN Number

INE901L01018

Website

http://alembicpharmaceuticals.com

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Rp946,50

44.29%

Last Update: 04/07/2026

Analysts: 10

Highest Price Target Rp1.132,00

Average Price Target Rp946,50

Lowest Price Target Rp720,00

In the last five quarters, Alembic Pharmaceuticals’s Price Target has fallen from Rp853,67 to Rp742,44 - a -13,03% decrease. Eight analysts predict that Alembic Pharmaceuticals’s share price will increase in the coming year, reaching Rp946,50. This would represent an increase of 44,29%.

Top growth stocks in the health care sector (5Y.)

What does Alembic Pharmaceuticals do?

Alembic Pharmaceuticals Limited (Alembic) is a leading Indian pharmaceutical company engaged in the development, manufacturing, and marketing of a broad range of pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company is showcasing a commitment to quality and innovation within the pharmaceutical sector. The company is primarily focused on both domestic and international markets, with significant emphasis on the U.S. generics business, where it has established a commendable presence. Alembic operates its primary manufacturing facilities in India, which are equipped with sophisticated technology conducive to the production of quality pharmaceuticals tailored to meet global standards.

Business Segments

The company operates primarily through two significant business segments: formulations and APIs.

Formulations

This segment develops a wide range of prescription and over-the-counter (OTC) products. This includes therapeutic categories such as oncology, dermatology, ophthalmology, and respiratory treatments. The company has been actively expanding its product portfolio and has successfully launched several new products annually. For instance, Alembic launched about 27 products specifically in the U.S. market in the fiscal year 2024, showcasing its commitment to innovation and meeting unmet medical needs.

APIs

This segment involves the manufacture of active pharmaceutical ingredients that serve as the foundational components for various pharmaceutical formulations. The company’s capability to produce APIs allows it to maintain better cost control and supply chain efficiency, which is vital in today's competitive landscape.

Business Strategy

The strategy of the company is primarily driven by a robust framework aimed at sustaining growth and enhancing market presence in both domestic and international segments. A critical focus area is the continuous development of a diversified product portfolio that balances the introduction of novel medicines with the management of existing generics. This strategic diversification is essential in providing a buffer against the persistent price pressures prevalent within the pharmaceutical sector, especially in the U.S. generics market.

Innovative product development is facilitated through an incisive R&D plan that emphasizes complex generics, including injectables, inhalational products, and specialty pharmaceuticals. By honing in on less congested segments within the market, Alembic aims to maximize returns on its investments and gradually transition towards more sophisticated offerings, further de-risking its business model.

Alongside product innovation, Alembic is committed to enhancing efficiencies. The commissioning of the greenfield plant in Pithampur is a strategic initiative expected to lower logistics costs and shorten product delivery times, thereby improving overall customer satisfaction. The integration of data-driven decision-making via IT solutions enables the company to hone processes and improve on-field performance effectively.

Furthermore, the emphasis on quality assurance and regulatory compliance remains paramount. Alembic constantly updates its practices to align with global standards, thus fortifying its reputation as a reliable supplier in the pharmaceutical market. The overarching strategy envisions maintaining momentum in growth trajectories while reinforcing the company's commitment to quality, safety, and innovation.

Products and Services

The company offers a diverse range of products and services, categorically divided into formulations and active pharmaceutical ingredients. In the formulations segment, the company specializes in delivering prescription medicines across multiple therapeutic areas, including but not limited to cardiology, psychiatry, gynecology, and urology. The company’s pediatric formulations and extensive generics portfolio are specifically designed to cater to various demographic segments, ensuring accessibility to medications for patients worldwide.

For the U.S. market, Alembic’s product range includes oncology treatments, which are vital given the rising incidence of cancer. The provision of both oral solid dosages and injectable medications illustrates the company’s comprehensive approach to treatment modalities in life-threatening diseases. Moreover, the dermatology segment focuses on topical solutions and medications aimed at addressing skin-related issues, showcasing Alembic’s commitment to catering to diverse healthcare needs.

In addition to formulations, Alembic’s manufacturing of APIs enhances its ability to create self-sufficiency within its operations. The company actively invests in the development of quality APIs that meet rigorous international standards. This vertical integration not only ensures compliance but also allows Alembic to better manage supply chains and costs, providing a competitive edge in the pharmaceutical market.

Geographical Markets Served

The company serves a myriad of geographical markets, with significant emphasis on India and the United States. While India serves as the home territory, the company has actively expanded its operations in international markets, particularly in the U.S., which is recognized as a key growth frontier.

Customers

The company serves a wide range of customers across various categories, including hospitals, clinics, pharmacies, and healthcare providers. The company focuses on both B2B and B2C segments, ensuring that its products reach end-users effectively.

Sales and Marketing

The company employs a multi-channel marketing strategy to promote its products. This encompasses direct sales efforts through a trained field force, digital marketing initiatives, and participation in trade shows and industry conferences to build brand visibility. The company emphasizes informative strategies and educational campaigns directed at healthcare providers to facilitate understanding of its products. Distribution channels are optimized for broad access to pharmacies and healthcare facilities, ensuring that products are easily accessible to consumers across various regions.

Government Regulations

The company strictly adheres to governmental regulations and compliance standards prevalent in the pharmaceutical industry. The company’s operations are monitored under various health and safety regulations, both at domestic and international levels. Compliance to Good Manufacturing Practices (GMP) and obtaining necessary certifications are critical aspects of its operational framework.

History

Alembic Pharmaceuticals Limited was founded in 1907. The company was incorporated in 2010.

Alembic Pharmaceuticals Questions and Answers

Which sectors generate sales and which are the top 3 markets?

**Pharmaceutical Industry:** 100% **TOP 3 Markets:** 1. **India:** approx. 35% 2. **USA:** approx. 30% 3. **Europe:** approx. 15% Alembic Pharmaceuticals Limited generates its revenues entirely from the pharmaceutical industry. The company operates in several international markets, with I...

At which locations are the company’s products manufactured?

**Production sites of Alembic Pharmaceuticals Limited:** 1. **Vadodara, Gujarat, India** 2. **Panelav, Gujarat, India** 3. **Sikkim, India** Alembic Pharmaceuticals Limited operates multiple production facilities in India. The main production sites are located in Vadodara and Panelav, both in the...

What strategy does Alembic Pharmaceuticals pursue for future growth?

**Revenue Growth:** Estimated 10-12% annually (2026, based on historical data and market trends) **Focus on R&D Investments:** 10-12% of revenue (estimated for 2026) Alembic Pharmaceuticals Limited pursues a growth strategy that heavily relies on research and development (R&D). The company...

Which raw materials are imported and from which countries?

**Main raw materials:** Active Pharmaceutical Ingredients (APIs), excipients **Main importing countries:** China, USA, Europe Alembic Pharmaceuticals Limited mainly imports Active Pharmaceutical Ingredients (APIs) and excipients needed for the production of their pharmaceutical products. A signifi...

How strong is the company’s competitive advantage?

**Market share in India:** 3.5% (2025, estimated) **R&D expenses:** 12% of revenue (2025) **Export share of revenue:** 40% (2025) Alembic Pharmaceuticals Limited has a significant competitive advantage due to its strong presence in the Indian market and its continuous investments in researc...

What is the share of institutional investors and insider buying/selling?

**Institutional Investor Share:** Estimated at around 35% (2026) **Insider Purchases/Sales:** No significant activities reported (2026) The institutional investor share in Alembic Pharmaceuticals Limited is estimated to be around 35%. This indicates a moderate interest from institutional investors...

What percentage market share does Alembic Pharmaceuticals have?

**Market share of Alembic Pharmaceuticals Limited:** Estimated 2-3% (2026) **Top competitors and their market shares:** 1. **Sun Pharmaceutical Industries Ltd.:** 8-10% 2. **Dr. Reddy's Laboratories:** 6-8% 3. **Cipla Ltd.:** 5-7% 4. **Lupin Ltd.:** 4-6% 5. **Aurobindo Pharma Ltd.:** 4-5% 6. *...

Is Alembic Pharmaceuticals stock currently a good investment?

**Revenue Growth:** 8.5% (2025) **R&D Expenses:** 12% of revenue (2025) **Market Share in India:** 5% (2025) Alembic Pharmaceuticals Limited has recorded a solid revenue growth of 8.5% in 2025 in recent years. This indicates stable demand for their products, especially in the generics and speci...

Does Alembic Pharmaceuticals pay a dividend – and how reliable is the payout?

**Dividend Yield:** 1.5% (estimated for 2026) **Dividend History:** Regular payouts over the last 5 years Alembic Pharmaceuticals Limited has regularly distributed dividends in recent years, indicating a reliable dividend policy. The estimated dividend yield for 2026 is around 1.5%, based on the l...

New support ticket

Explore

Alembic Pharmaceuticals Stock Value

Alembic Pharmaceuticals Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Alembic Pharmaceuticals do?

Alembic Pharmaceuticals Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

Alembic Pharmaceuticals Stock Value

Alembic Pharmaceuticals Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Alembic Pharmaceuticals do?

Alembic Pharmaceuticals Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.